Medicus Pharma shares surge 15.98% after-hours on positive Phase 2 SkinJect data showing 73% clinical clearance.

Medicus Pharma (NASDAQ:MDCX) surged 16.0% in after-hours trading following the release of positive Phase 2 data for its SkinJect microneedle platform in basal cell carcinoma, which demonstrated 73% clinical clearance in the 200-µg cohort, and the announcement of its CEO’s participation in the Longwood Miami CEO Forum. The trial results highlighted SkinJect’s efficacy beyond placebo effects, reinforcing its potential as a non-surgical treatment and advancing regulatory discussions. Concurrently, the CEO’s focus on AI-enabled drug development at the forum underscored the company’s innovation in streamlining clinical trials, attracting investor optimism. These developments collectively drove the sharp post-market rally, reflecting confidence in Medicus’ therapeutic pipeline and strategic advancements.